Drug intelligence / Profile preview

PXS25

Development stage: Discontinued
Lead developer: Syntara
Modality: Small Molecules
Administration: Oral

Overview

PXS25 is a small molecule inhibitor of the cation-independent mannose 6-phosphate receptor (CI-M6PR), developed by Pharmaxis Ltd for the treatment of lung fibrosis and the prevention of scar tissue formation. The compound acts by preventing the CI-M6PR-mediated conversion of latent TGF-β1 into its active, pro-fibrotic form. Despite demonstrating anti-fibrotic properties in research settings, the clinical development of PXS25 was limited by low bioavailability, leading to the termination of the program.

Other names: PXS25PXS-25PXS 25

Targets

IGF2R (Cation-independent mannose-6-phosphate receptor)

Beyond the preview

Go deeper on PXS25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PXS25.

Explore the full profile